Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm trastuzumab emtansine in HER2-positive advanced or metastatic NSCLC
2014-001237-83Phase 2Completed
- Sponsor
- Roche
- Start
- Aug 2014
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab emtansine in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Aug 2014; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-001237-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001237-83.